On the evening of March 18, the listed company Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) (” Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) “, sh Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) , hk0874) of Guangzhou Pharmaceutical Group released the performance report for 2021. According to the data, the company achieved an operating revenue of 69.014 billion yuan in 2021, a year-on-year increase of 11.90%; The total profit was 4.723 billion yuan, a year-on-year increase of 26.32%; The net profit attributable to the shareholders of the company was 3.720 billion yuan, a year-on-year increase of 27.60%, and the net cash flow from operating activities reached 5.673 billion yuan, a year-on-year increase of 869.52%.
During the reporting period, Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) insisted on deep cultivation and meticulous cultivation of the Great Southern medicine sector, and promoted the sales growth of key varieties by focusing on resources to create core varieties, strengthening channel development and maintenance, strengthening terminal promotion and promotion, and tapping the potential of second-line echelon products. The sales revenue of Jinge, Zishen Yutai pill, Xiaochaihu granule, amoxicillin series, Baoji series, cefuroxime sodium for injection, Huatuozaizao pill and other products achieved double-digit growth year-on-year.
The growth of large varieties is inseparable from scientific research and innovation. It is reported that the R & D expenses of Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) 2021 reached 875 million yuan, a year-on-year increase of 42.94%. Hanfang National Engineering Research Center was optimized and integrated by the national development and Reform Commission and renamed “National Engineering Research Center for traditional Chinese medicine pharmaceutical process technology and new drug creation”, which was included in the new sequence management. The General Hospital of Guangzhou Pharmaceutical has obtained GLP full qualification certification, and the research level of drug non clinical safety evaluation ranks among the forefront of the country. Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) biomedicine and health R & D and sales headquarters has been capped. After completion, it will further improve its independent R & D strength, product competitiveness and resource integration.
